Medicine Recommendations

Treatment of adrenal insufficiency in adults.

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of post menopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Postmenopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Pain

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Reversal of the anticoagulant effect of Dabigatran

Raynauds

Depressive illness

Treatment of Actinic Keratosis

Treatment of small superficial basal-cell carcinomas in adults

Rheumatoid arthritis (LSCMMG pathway)

Psoriatic arthritis (NICE TA199)

NICE TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .

Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.